S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Trade With Artificial Intelligence for Happiness (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
Trade With Artificial Intelligence for Happiness (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Trade With Artificial Intelligence for Happiness (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Trade With Artificial Intelligence for Happiness (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
Trade With Artificial Intelligence for Happiness (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Trade With Artificial Intelligence for Happiness (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Trade With Artificial Intelligence for Happiness (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
Trade With Artificial Intelligence for Happiness (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Trade With Artificial Intelligence for Happiness (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Trade With Artificial Intelligence for Happiness (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
Trade With Artificial Intelligence for Happiness (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Trade With Artificial Intelligence for Happiness (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
NASDAQ:CTIC

CTI BioPharma - CTIC Stock Forecast, Price & News

$5.82
+0.19 (+3.37%)
(As of 09/30/2022 09:01 PM ET)
Add
Compare
Today's Range
$5.62
$6.12
50-Day Range
$5.36
$7.43
52-Week Range
$1.43
$7.80
Volume
5.10 million shs
Average Volume
4.61 million shs
Market Capitalization
$665.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.71

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
84.1% Upside
$10.71 Price Target
Short Interest
Bearish
14.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of CTI BioPharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$46.67 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.78) to $0.25 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

204th out of 1,095 stocks

Pharmaceutical Preparations Industry

79th out of 547 stocks

CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

Analyst Ratings: What Are They?
What 4 Analyst Ratings Have To Say About CTI BioPharma
CTI BioPharma: Q2 Earnings Insights
CTI BioPharma: One Trick Pony Ready To Perform
Why CTI BioPharma Stock Blasted 18% Higher Today
Why CTI Biopharma Stock Is Surging Today
CTI BioPharma Q1 2022 Earnings Preview
Keep an eye on the momentum at Cti Biopharma
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Company Calendar

Last Earnings
8/08/2022
Today
10/03/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
22
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$10.71
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+84.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-97,910,000.00
Pretax Margin
-826.01%

Debt

Sales & Book Value

Annual Sales
$3.35 million
Book Value
$0.04 per share

Miscellaneous

Free Float
102,718,000
Market Cap
$665.72 million
Optionable
Optionable
Beta
0.87

Social Links


Key Executives

  • Dr. Adam R. Craig M.B.A. (Age 56)
    M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director
    Comp: $1.02M
  • Mr. David H. Kirske (Age 68)
    Exec. VP, CFO & Sec.
    Comp: $542.34k
  • Mr. Bruce J. Seeley (Age 58)
    Exec. VP & COO
    Comp: $642.36k
  • Mr. Ed Bell
    Sr. Director of Investor Relations
  • Mr. James K. Fong (Age 60)
    Sr. VP & Chief Commercial Officer
  • Mr. Bruce K. Bennett Jr. (Age 70)
    Sr. VP Global Pharmaceutical Operations
  • Mr. John Volpone
    Sr. VP of Strategic Operations
  • Dr. Jennifer A. Smith
    Sr. VP of Biometrics













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2022?

7 brokerages have issued 12 month price objectives for CTI BioPharma's shares. Their CTIC share price forecasts range from $9.00 to $13.00. On average, they anticipate the company's stock price to reach $10.71 in the next year. This suggests a possible upside of 84.1% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How have CTIC shares performed in 2022?

CTI BioPharma's stock was trading at $2.48 at the beginning of the year. Since then, CTIC stock has increased by 134.7% and is now trading at $5.82.
View the best growth stocks for 2022 here
.

When is CTI BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CTIC earnings forecast
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings data on Monday, August, 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. During the same period last year, the firm earned ($0.21) EPS.

When did CTI BioPharma's stock split?

CTI BioPharma's stock reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

How do I buy shares of CTI BioPharma?

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $5.82.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $665.75 million and generates $3.35 million in revenue each year. The biopharmaceutical company earns $-97,910,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.